|
Real-time Estimate
Cboe BZX
00:52:24 02/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 1.885 USD | +1.89% |
|
-1.30% | +21.47% |
| 09-17 | Novartis halts ALS drug development after mid-stage trial failure | RE |
| 09-15 | Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 207M | - | - | |||
| 74.46B | |||||
| 60.14B | |||||
| 48.15B | |||||
| 44.25B | |||||
| 43.99B | - | - | - | - | - |
- Stock Market
- Stocks
- ALEC Stock
- Charts Alector, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
